2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
193
Neoplasm Metastasis
22
Prostatic Neoplasms, Castration-Resistant
20
Breast Neoplasms
19
Neoplasms
17
Metastatic Castration Resistant Prostate Cancer
10
Prostate Cancer Metastatic
7
Metastatic Castration-Resistant Prostate Cancer
7
Triple Negative Breast Neoplasms
6
Metastatic Castration-resistant Prostate Cancer
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Pancreatic Neoplasms
5
Castration-resistant Prostate Cancer
5
Carcinoma, Non-Small-Cell Lung
5
Melanoma
4
Colorectal Neoplasms
4
Bulbo-Spinal Atrophy, X-Linked
4
Adenocarcinoma
4
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Prostate Adenocarcinoma
3
Ovarian Neoplasms
3
Carcinoma, Hepatocellular
3
mCRPC
2
Uterine Cervical Neoplasms
2
Recurrence
2
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Metastatic Hormone-sensitive Prostate Cancer
2
Interventions
Sirolimus
4
LY3295668 erbumine
3
Everolimus
3
Medical Marijuana
2
Anticonvulsants
2
ziprasidone
1
perampanel
1
enzalutamide
1
clevidipine
1
brivaracetam
1
Zolpidem
1
Warfarin
1
Vigabatrin
1
Vecuronium Bromide
1
Vancomycin
1
Tranexamic Acid
1
Topotecan
1
Tobramycin
1
Therapeutic Touch
1
Temozolomide
1
TAS-119
1
Surgical Procedures, Operative
1
Sulfasalazine
1
Spironolactone
1
Sevoflurane
1
Sevelamer
1
Saline Solution
1
Rocuronium
1
Registries
1
Radiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Epilepsy
×
enzalutamide
×
Clear all
NCT04290611
2023-04-13
VENDY
Groupe Hospitalier Pitie-Salpetriere
Completed
500,000 enrolled